shutterstock_1873015870_alpha_tauri_3d_graphics
Alpha Tauri 3D Graphics / Shutterstock.com
23 August 2022FeaturesBiotechnologyIne Vanderleyden

Microbial consortia and IP in Europe

Our body hosts trillions of microorganisms that live symbiotically on and within the human body. This ‘microbiome’ is essential to our health and microbial imbalance or dysbiosis increases the susceptibility to many diseases, including inflammatory bowel disease (IBD), liver disease, atherosclerosis, and other severe pathologies. Given its central role in health and disease, the microbiome has become a prominent therapeutic target.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
6 May 2020   The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.
Biotechnology
27 October 2022   Developments in microbiome tech are aimed at reducing the need for antibiotics in livestock farming and have led to some notable patenting trends and requirements, explains Rosie McDowell of EIP.

More on this story

Big Pharma
6 May 2020   The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.
Biotechnology
27 October 2022   Developments in microbiome tech are aimed at reducing the need for antibiotics in livestock farming and have led to some notable patenting trends and requirements, explains Rosie McDowell of EIP.

More on this story

Big Pharma
6 May 2020   The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.
Biotechnology
27 October 2022   Developments in microbiome tech are aimed at reducing the need for antibiotics in livestock farming and have led to some notable patenting trends and requirements, explains Rosie McDowell of EIP.